Department of Radiology and Medical Imaging, Ghent University Hospital and Ghent University, Ghent, Belgium.
Department of Radiology and Medical Imaging, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
Skeletal Radiol. 2022 Jan;51(1):101-122. doi: 10.1007/s00256-021-03903-8. Epub 2021 Sep 14.
The last decades, increasing research has been conducted on dynamic contrast-enhanced and diffusion-weighted MRI techniques in multiple myeloma and its precursors. Apart from anatomical sequences which are prone to interpretation errors due to anatomical variants, other pathologies and subjective evaluation of signal intensities, dynamic contrast-enhanced and diffusion-weighted MRI provide additional information on microenvironmental changes in bone marrow and are helpful in the diagnosis, staging and follow-up of plasma cell dyscrasias. Diffusion-weighted imaging provides information on diffusion (restriction) of water molecules in bone marrow and in malignant infiltration. Qualitative evaluation by visually assessing images with different diffusion sensitising gradients and quantitative evaluation of the apparent diffusion coefficient are studied extensively. Dynamic contrast-enhanced imaging provides information on bone marrow vascularisation, perfusion, capillary resistance, vascular permeability and interstitial space, which are systematically altered in different disease stages and can be evaluated in a qualitative and a (semi-)quantitative manner. Both diffusion restriction and abnormal dynamic contrast-enhanced MRI parameters are early biomarkers of malignancy or disease progression in focal lesions or in regions with diffuse abnormal signal intensities. The added value for both techniques lies in better detection and/or characterisation of abnormal bone marrow otherwise missed or misdiagnosed on anatomical MRI sequences. Increased detection rates of focal lesions or diffuse bone marrow infiltration upstage patients to higher disease stages, provide earlier access to therapy and slower disease progression and allow closer monitoring of high-risk patients. Despite promising results, variations in imaging protocols, scanner types and post-processing methods are large, thus hampering universal applicability and reproducibility of quantitative imaging parameters. The myeloma response assessment and diagnosis system and the international myeloma working group provide a systematic multicentre approach on imaging and propose which parameters to use in multiple myeloma and its precursors in an attempt to overcome the pitfalls of dynamic contrast-enhanced and diffusion-weighted imaging.Single sentence summary statementDiffusion-weighted imaging and dynamic contrast-enhanced MRI provide important additional information to standard anatomical MRI techniques for diagnosis, staging and follow-up of patients with plasma cell dyscrasias, although some precautions should be taken on standardisation of imaging protocols to improve reproducibility and application in multiple centres.
过去几十年,针对多发性骨髓瘤及其前体的动态对比增强和弥散加权 MRI 技术进行了越来越多的研究。除了由于解剖变异、其他病理学和信号强度的主观评估而容易产生解读错误的解剖序列外,动态对比增强和弥散加权 MRI 还提供了骨髓微环境变化的额外信息,有助于浆细胞异常的诊断、分期和随访。弥散加权成像提供了骨髓和恶性浸润中水分子弥散(受限)的信息。广泛研究了通过不同弥散敏感梯度评估图像的定性评估和表观弥散系数的定量评估。动态对比增强成像提供了骨髓血管化、灌注、毛细血管阻力、血管通透性和间质空间的信息,这些信息在不同疾病阶段都会发生系统性改变,可以进行定性和(半)定量评估。弥散受限和异常动态对比增强 MRI 参数都是局灶性病变或弥漫性异常信号强度区域中恶性或疾病进展的早期标志物。这两种技术的附加值在于更好地检测和/或表征在解剖学 MRI 序列上错过或误诊的异常骨髓。对异常骨髓的检测率增加使患者分期更高,更早获得治疗机会,疾病进展更缓慢,并允许对高危患者进行更密切的监测。尽管有很有前景的结果,但成像方案、扫描仪类型和后处理方法的差异很大,从而阻碍了定量成像参数的普遍适用性和可重复性。骨髓瘤反应评估和诊断系统以及国际骨髓瘤工作组提供了一种系统的多中心成像方法,并提出了在多发性骨髓瘤及其前体中使用哪些参数的建议,以试图克服动态对比增强和弥散加权成像的缺陷。
单句摘要陈述弥散加权成像和动态对比增强 MRI 为浆细胞异常患者的标准解剖学 MRI 技术的诊断、分期和随访提供了重要的附加信息,尽管应该在成像方案的标准化方面采取一些预防措施,以提高可重复性和在多个中心的应用。